drug

IMNN-001

1 story · latest Aug 11, 2026

Status: Investigational
Trials: 2 registered trials in coverage

Relationships

Developed by Imunon

Timeline

Imunon reports Q2 2026 results, cites OVATION 3 enrollment pace and new MRD data

Aug 11Quarterly updateImunon

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.